Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 8/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.36 |
| ▸ | TMPRSS15 | P98073 | 4/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL1661921 | 1.00 | LTA4H (0.40) | LTA4HPRSS1TMPRSS15ITGB3ITGA2B | |
| Arginine SCHEMBL1661915 | 1.00 | LTA4H (0.40) | LTA4HPRSS1TMPRSS15ITGB3ITGA2B | |
| Arginine SCHEMBL1661333 | 1.00 | LTA4H (0.40) | LTA4HPRSS1TMPRSS15ITGB3ITGA2B | |
| Arginine SCHEMBL13519168 | 0.93 | LTA4H (0.41) | LTA4HPRSS1TMPRSS15ITGB3ITGA2B | |
| Arginine SCHEMBL13518780 | 0.93 | LTA4H (0.41) | LTA4HPRSS1TMPRSS15ITGB3ITGA2B | |
| Arginine SCHEMBL13518858 | 0.93 | LTA4H (0.41) | LTA4HPRSS1TMPRSS15ITGB3ITGA2B | |
| Arginine SCHEMBL13518762 | 0.93 | LTA4H (0.41) | LTA4HPRSS1TMPRSS15ITGB3ITGA2B | |
| Phenethylamine SCHEMBL1663279 | 0.93 | NPC1 (0.39) | LTA4HPRSS1TMPRSS15NPC1RAB9A | |
| Phenethylamine SCHEMBL1661930 | 0.93 | NPC1 (0.39) | LTA4HPRSS1TMPRSS15NPC1RAB9A | |
| Arginine SCHEMBL13519205 | 0.91 | LTA4H (0.40) | LTA4HPRSS1TMPRSS15ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120277164-A1 | GADD45BETA TARGETING AGENTS | IMPERIAL INNOVATIONS LIMITED (GB) | 2012-11-01 | — | — | US | claimed |
| US-10697019-B2 | Method of diagnosis and prognosis | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2020-06-30 | — | — | US | disclosed |
| US-20170240592-A1 | GADD45BETA/MKK7 INHIBITOR FOR THE TREATMENT OF A RESISTANT HAEMATOLOGICAL MALIGNANCY | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2017-08-24 | — | — | US | disclosed |
| EP-3180350-A1 | GADD45BETA/MKK7 INHIBITOR FOR THE TREATMENT OF A RESISTANT HAEMATOLOGICAL MALIGNANCY | Imperial Innovations Ltd (GB) | 2017-06-21 | — | — | EP | disclosed |
| EP-3178836-A1 | GADD45BETA TARGETING AGENTS | Imperial Innovations Limited (GB) | 2017-06-14 | — | — | EP | disclosed |
| EP-2702167-B1 | METHODS OF DIAGNOSIS AND PROGNOSIS OF MULTIPLE MYELOMA, BY MEASURING GADD45BETA EXPRESSION | IMP INNOVATIONS LTD (GB) | 2016-12-28 | — | — | EP | disclosed |
| US-9518083-B2 | Gadd45beta targeting agents | IMPERIAL INNOVATIONS LIMITED (GB) | 2016-12-13 | — | — | US | disclosed |
| WO-2016024131-A1 | GADD45BETA/MKK7 INHIBITOR FOR THE TREATMENT OF A RESISTANT HAEMATOLOGICAL MALIGNANCY | IMPERIAL INNOVATIONS LIMITED (GB) | 2016-02-18 | — | — | WO | disclosed |
| US-20150368294-A1 | GADD45BETA TARGETING AGENTS | IP2IPO INNOVATIONS LIMITED (GB) | 2015-12-24 | — | — | US | disclosed |
| US-8993717-B2 | Gadd45beta targeting agents | IMPERIAL INNOVATIONS LIMITED (GB) | 2015-03-31 | — | — | US | disclosed |
| US-20140128330-A1 | METHOD OF DIAGNOSIS AND PROGNOSIS | IMPERIAL INNOVATIONS LIMITED (GB) | 2014-05-08 | — | — | US | disclosed |
| EP-2702167-A2 | METHOD OF DIAGNOSIS AND PROGNOSIS | Imperial Innovations Limited (GB) | 2014-03-05 | — | — | EP | disclosed |
| WO-2012146940-A2 | METHOD OF DIAGNOSIS AND PROGNOSIS | IMPERIAL INNOVATIONS LIMITED (GB) | 2012-11-01 | — | — | WO | disclosed |
| US-20120277164-A1 | GADD45BETA TARGETING AGENTS | IMPERIAL INNOVATIONS LIMITED (GB) | 2012-11-01 | — | — | US | disclosed |
| EP-2491051-A2 | GADD45BETA TARGETING AGENTS | Imperial Innovations Limited (GB) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011048390-A2 | GADD45BETA TARGETING AGENTS | IMPERIAL INNOVATIONS LIMITED (GB) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240592-A1 | GADD45BETA/MKK7 INHIBITOR FOR THE TREATMENT OF A RESISTANT HAEMATOLOGICAL MALIGNANCY | MCL1, DDIT3, MAP2K7 | LTA4H 4730/4885PRSS1 3545/4885TMPRSS15 3623/4885 |
| US-20150368294-A1 | GADD45BETA TARGETING AGENTS | DDB1, CCL2, DDIT3 | LTA4H 3394/4885PRSS1 3374/4885TMPRSS15 1339/4885 |
| US-20120277164-A1 | GADD45BETA TARGETING AGENTS | DDB1, CCL2, DDIT3 | LTA4H 3394/4885PRSS1 3374/4885TMPRSS15 1339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.